市場調查報告書
商品編碼
1395025
一次性生物反應器市場- 副產品(攪拌槽、波混合、鼓泡塔)、細胞(哺乳動物、細菌、酵母)、分子(單株抗體、疫苗、重組蛋白)、用途、最終用途- 全球預測, 2023 年-2032Single-use Bioreactors Market - By Product (Stirred Tank, Wave-mixed, Bubble Column), Cell (Mammalian, Bacterial, Yeast), Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins), Usage, End-use- Global Forecast, 2023-2032 |
在醫療保健領域的顯著進步和一次性生物加工技術固有的靈活性的推動下,全球一次性生物反應器市場從 2023 年到 2032 年的CAGR將達到 15.5%。在精準醫學和治療創新激增的推動下,對生物製藥的需求不斷成長,凸顯了這些進步的重要性。一次性生物反應器由於其適應性強且具有成本效益的性質,成為滿足醫療保健行業不斷變化的需求的關鍵工具,從而為行業格局做出了重大貢獻。
例如,2023 年,Getinge 推出了 AppliFlex ST GMP,這是一種創新的一次性生物反應器系統,旨在順利連接細胞和基因治療的研究和臨床生產領域以及 mRNA 生產。此次發布透過無縫整合尖端醫療保健進步和一次性生物加工技術的內在靈活性來提高市場佔有率。
一次性生物反應器市場根據分子、細胞和區域進行分類。
到 2032 年,單株抗體 (mAb) 領域將獲得大幅成長。這種突出地位源自於 mAb 的治療應用不斷增加,特別是在治療癌症和自體免疫疾病方面。它們的高特異性、治療功效以及對個人化醫療不斷成長的需求使其在生物加工領域中佔據突出地位。隨著製藥領域優先考慮精準和標靶治療,單株抗體在一次性生物反應器中的作用變得至關重要,從而塑造了生物反應器的市場前景。
由於細菌細胞在各種生物加工活動中的廣泛應用,包括疫苗、酵素和生物治療藥物的生產,到 2032 年,細菌細胞細分市場將獲得可觀的收入佔有率。利用細菌細胞的多功能性、可擴展性和成本效益使其脫穎而出。隨著對生物製藥的需求不斷升級,基於細菌細胞的製程的盛行將使它們成為塑造健康市場成長軌跡的關鍵驅動力。
受多種因素的推動,包括生物製藥需求的成長、研發投資的增加以及生物技術產業的蓬勃發展,亞太地區一次性生物反應器市場規模將從 2023 年到 2032 年以顯著的CAGR擴大。有利的監管環境,加上該地區強大的製造能力,有助於其突出地位。隨著全球製藥格局的不斷發展,亞太市場成為關鍵貢獻者,推動創新並塑造一次性生物反應器的未來。
Global Single-use Bioreactors Market will register a 15.5% CAGR from 2023 to 2032, propelled by the remarkable advancements in healthcare and the inherent flexibility of single-use bioprocessing technologies. The increasing demand for biopharmaceuticals, driven by a surge in precision medicine and therapeutic innovations, underscores the significance of these advancements. Single-use bioreactors, owing to their adaptable and cost-effective nature, emerge as pivotal tools in meeting the evolving needs of the healthcare sector, thereby significantly contributing to the industry landscape.
For instance, in 2023, Getinge launched the AppliFlex ST GMP, an innovative single-use bioreactor system crafted to smoothly connect the realms of research and clinical production in cell and gene therapy, along with mRNA production. This launch bolsters the market share by seamlessly integrating cutting-edge healthcare advancements and the intrinsic flexibility of single-use bioprocessing technologies.
The single-use bioreactors market is segregated based on molecule, cell, and region.
The monoclonal antibodies (mAbs) segment will garner substantial gains through 2032. This prominence stems from the increasing therapeutic applications of mAbs, particularly in treating cancer and autoimmune diseases. Their high specificity, therapeutic efficacy, and rising demand for personalized medicine contribute to their prominence in bioprocessing. As the pharmaceutical landscape prioritizes precision and targeted therapies, the role of monoclonal antibodies within single-use bioreactors becomes pivotal, shaping the bioreactors market outlook.
The bacterial cell segment will capture a remarkable revenue share by 2032 due to the widespread application of bacterial cells in various bioprocessing activities, including the production of vaccines, enzymes, and biotherapeutics. The versatility, scalability, and cost-effectiveness of utilizing bacterial cells contribute to their prominence. As the demand for biopharmaceuticals continues to escalate, the prevalence of bacterial cell-based processes will position them as a pivotal driver in carving a healthy market growth trajectory.
APAC single-use bioreactors market size will expand at a notable CAGR from 2023 to 2032, fueled by a confluence of factors, including the growing demand for biopharmaceuticals, increasing investments in research and development, and a burgeoning biotechnology sector. Favorable regulatory environments, in line with the region's robust manufacturing capabilities, contribute to its prominence. As the global pharmaceutical landscape continues to evolve, the Asia-Pacific market stands as a key contributor, driving innovation and shaping the future of single-use bioreactors.